Meet the Start-ups

Pierre Vandepapelière | CEO | Amyl Therapeutics

Pierre Vandepapelière, M.D., PhD, Dip Trop Med, is co-founder, CEO and CMO of Amyl Therapeutics since 2020. He has a more than 30 years’ experience in vaccine and biological therapeutics development and management in the large Pharma and Biotech industries.

At GSK Vaccines he was head of early clinical research and has led the development of early and late phase prophylactic and therapeutic vaccines worldwide. As CEO and CMO of Imcyse, he transformed an academic research group into a rapidly growing Biotech company, signing major partnerships with pharma companies and closing a €35M series B. In Paris, Pierre also led the Biotechs’ development of immunotherapeutics for auto immune diseases and for chronic viral infections.

Amyl Therapeutics

Amyl therapeutics, based in Liège, Belgium, was founded in 2020 and is developing a breakthrough platform of fusion proteins for the treatment of amyloid mediated diseases, ie amyloidosis and neurodegenerative diseases. With a very experienced pharma and biotech team, we combine internal and outsourced development. We have demonstrated the value and mode of action of the platform in AL amyloidosis, and we are moving to clinical development.

Given the recent positive developments in Alzheimer’s disease, Amyl therapeutic ground breaking technology also has the potential to become the next-generation treatment for several neurodegenerative disorders.